Emerald Advisers Portfolio holdings
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$9.23M |
| 2 |
ASRT
Assertio
ASRT
|
+$8.76M |
| 3 |
ITMN
INTERMUNE INC
ITMN
|
+$8.58M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
+$8.51M |
| 5 |
Kforce
KFRC
|
+$8.18M |
Top Sells
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$40.2M |
| 2 |
AKRX
Akorn Inc
AKRX
|
+$21.7M |
| 3 |
BCOV
Brightcove, Inc.
BCOV
|
+$10.6M |
| 4 |
REXX
Rex Energy Corporation
REXX
|
+$8.91M |
| 5 |
Meritage Homes
MTH
|
+$8.41M |
Sector Composition
| 1 | Industrials | 17.87% |
| 2 | Technology | 15.37% |
| 3 | Healthcare | 14.23% |
| 4 | Financials | 11.54% |
| 5 | Consumer Discretionary | 10.77% |
Similar funds
Emerald Advisers's Q1 2014 Portfolio in Review
As of Q1 2014, Emerald Advisers held 390 positions worth $1.78B, down 3.7% from $1.85B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Emerald Advisers withdrew a net $132M in Q1 2014, closing 34 positions and reducing 174 holdings. Its most notable exit was Akorn Inc, an estimated $21.7M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 18% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Emerald Advisers opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $12.4M.
- Emerald Advisers's largest Q1 2014 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 817,410 shares worth $12.4M.
- Emerald Advisers added most to PacWest Bancorp in Q1 2014, an estimated $7.25M increase.
- Emerald Advisers's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $40.2M.
- Emerald Advisers fully exited Akorn Inc in Q1 2014, selling an estimated $21.7M.
- Emerald Advisers's ten largest holdings make up 16% of its $1.78B portfolio in Q1 2014.
- Emerald Advisers opened 41 new positions and closed 34 in Q1 2014.
- Emerald Advisers's portfolio value fell 3.7% quarter-over-quarter to $1.78B.
Based on Emerald Advisers's 13F filing for Q1 2014, filed 30 Apr 2014.